Kornimate/medical-research-clean huggingface dataset:
the effect of frailty and other geriatric syndromes on the prognosis of elderly patients with acute coronary syndrome

Conditions: ACS; Frail Elderly Syndrome; Elderly Patient

Summary: this is a prospective observational clinical trail which will recruit 1000-1500 participants over 65 years with frailty and acute coronary syndrome (acs) in beijing friendship hospital. the investigators will conduct frailty assessment (frail scale, cfs, sppb), comorbidities, functional status (barthel index, adl, iadl), nutritional risk (mna-sf), and then observe the clinical outcomes of elderly acs participants with frailty. then, the investigators will follow-up these participants separately in 1,3,6 and 12months, the anticipate follow-up time is 1 year. according to the follow-up results, investigators will evaluate the impact of frailty and other senile syndromes on the short-term and long-term prognosis of acs, and develop a scoring system for the prognosis evaluation of elderly acs participants.


Eligibility criteria:
inclusion criteria: * elderly participants over 65 * clinical diagnosis of acute coronary syndrome * must be able to follow-up * sign in the informed consent exclusion criteria: * myocardial infarction caused by other acute disease * mental disorders who cannot cooperate to complete the assessment * severe liver dysfunction, kidney disease (ckd 5), end-stage malignant tumor * totally disabled and bedridden
use of video consultation in follow-up care for patients with a neuroendocrine tumor: a feasibility study

Conditions: Neuroendocrine Tumor

Summary: rationale: patients with neuroendocrine tumors (net) have a rare disease. due to treating patients with a neuroendocrine tumor in 'net knowledge centers' patients often have to travel long distances for follow-up visits at the outpatient clinic. patients whose medical condition allows videoconsultation could save time by replacing outpatient clinic visits through videoconsultation for receiving follow-up care. therefore, in this study we aim to introduce videoconsultation as a alternative for follow-up outpatient clinic visits in net patients. objective: the primary objective is to assess if use of videoconsultation in follow-up care for net patients is feasible. we hypothesize that videoconsultation is a suitable medium for providing follow-up care in net patients. secondary objectives are to explore the amount of time videoconsultation takes in comparison with outpatient clinic visits and the acceptability and satisfaction of physicians and patients with using videoconsultation in follow-up care. study design: the present study is a single-centre prospective feasibility study. study population: adult net patients under surveillance or treatment of the department medical oncology at the university medical centre groningen (umcg) whose medical condition allows videoconsultation will be invited to participate. intervention: patient who give informed consent will participate in the study. participants will receive follow-up care through videoconsultation instead of conventional visits at the outpatient clinic. main study parameters/endpoints: the main endpoint is the feasibility of videoconsultation for follow-up care in net patients. we hypothesize that videoconsultation is a suitable medium for providing follow-up care.


Eligibility criteria:
inclusion criteria: * signed informed consent * age ≥ 18 yrs * grade i or ii (low and intermediate grade) net with any primary tumor type or disease stage * have access to required equipment/technology for performing videoconsultation exclusion criteria: * newly referred net patients, who are visiting the department of medical oncology at the umcg for the first time * recently diagnosed net patients, who are in the diagnostic phase of the disease * net patients who frequently require blood tests, consultation or physical examination * a hearing or visual impairment, which would make videoconsultation difficult

Keywords: neuroendocrine tumor videoconsultation feasibility
positive psychology intervention to improve quality of life in stem cell transplant survivors and their caregivers

Conditions: Hematopoietic Cell Transplantation Recipient

Summary: this trial studies a positive psychology intervention designed to improve quality of life in stem cell transplant survivors and their caregivers. positive psychology (pp) uses systematic exercises (e.g., gratitude letters, acts of kindness) to potentially boost levels of optimism, resilience, and life enjoyment. pp interventions are often enjoyable, easy to understand, and can be delivered via telephone. pp intervention may improve the quality of life of participants who have undergone a stem cell transplant or their caregivers.

primary objectives: i. pilot a positive psychology intervention delivered to hematopoietic cell transplantation (hct) survivors and interested caregivers over an 8 week period. ii. determine the proportion of patients who enroll and the immediate benefit to participants, as measured by pre- and post-exercise measures of happiness and optimism. iii. pilot outcome data collection mechanisms in preparation for a randomized clinical trial. outline: participants and caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks. after completion of study, participants are followed up at 6 months.

Eligibility criteria:
inclusion criteria: * written informed consent * english as primary language * at least 1 year after hct exclusion criteria: * major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach. * medical conditions precluding participation in the intervention or likely to lead to death within 6 months, as determined by the principal investigator (pi)
respiratory rehabilitation for patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the aim of this clinical trial is to establish the non-inferiority of home-based respiratory rehabilitation compared to respiratory rehabilitation in center in terms of exercise tolerance as evaluated by the 6 minutes stepper test.. this trial will also 1°) evaluate the medico-economic aspects of the home-based respiratory rehabilitation versus respiratory rehabilitation in center; 2°) analyse the patient preferences between home-based respiratory rehabilitation and respiratory rehabilitation in center and 3°) compare home-based respiratory rehabilitation vs respiratory rehabilitation in center in terms of dyspnea, quality of life, anxiety and depression.

the purpose of this study is to perform a comparative analysis of the clinical and medico-economic effectiveness of center-based rr versus home-based rr in the departments of nord and pas de calais in france. all copd patients eligible for rr and willing to participate in the study will be followed. patient preferences will be evaluated at inclusion. after presentation of both rr modalities, patients expressing a strong preference for one or other of the terms will be taken care of according to their wishes. indifferent patients between the two rr modalities will be randomized. this design is justified in the light of three cases: * it is impossible to evaluate blind intervention, * the effectiveness of rr depends on patient preferences, * patients' adherence to the protocol is facilitated.

Eligibility criteria:
inclusion criteria:according to has recommendations, splf, ers / ats (3) (18) (19) can be included any patient, over 18 years old, with stage ii - iii - iv copd presenting disabling dyspnoea in activities of daily living, and / or in the course of acute exacerbation of copd (eabpco), with no other respiratory pathology diagnosed. exclusion criteria: according to the recommendations, has, splf, ers / ats will not be included any patient having : * co-morbidities including unstabilized cardiovascular disease, * significant cognitive disorders: patients with a history of pathologies neurodegenerative with loss of mental faculties (example: alzheimer) * psychiatric disorders: patients with impaired judgment and perception * neurological or orthopedic disorders that do not allow the realization of physical activities also, will not be included, the patient (s): * waiting for lung transplantation, * pregnant or nursing, * in an emergency situation * unable to receive enlightened information, * unable to participate in the entire study, * not covered by the social security scheme, * refusing to sign the consent,

Keywords: pulmonary rehabilitation home-based
efficacy of oral minocycline (solodyn) and oral minocycline (solodyn) plus azelaic acid (finacea) for acne rosacea

Conditions: Rosacea

Summary: rosacea is one of the most commonly occurring dermatoses treated by dermatologist today. rosacea is an inflammatory condition of the skin presenting as flushing and or blushing along with redness, swelling, telangiectasia, and acne lesions. minocycline has shown beneficial in the treatment of inflammatory acne lesions in patients with rosacea. this study is to evaluate the efficacy and tolerability of minocycline (solodyn) alone versus minocycline (solodyn) in combination with azelaic acid 15%(finacea) in the treatment of rosacea.

this is a multicenter, randomized, outpatient, investigator-blind study of minocycline 45 mg and minocycline 45 mg plus 15% azelaic acid for the treatment of rosacea.

Eligibility criteria:
inclusion criteria: * age 18 or older with clinical diagnosis of rosacea * must have 10-40 facial inflammatory lesions and less than 2 nodules * women of child bearing potential must be non lactating * must have negative urine pregnancy test * must use effective form of birth control exclusion criteria: * the use of systemic antibiotics within 30 days of study start * the use of topical medications within 14 - 30 days of study start depending on type of topical medication * patients with known sensitivity to tetracyclines * patients who have had gastric bypass surgery or are considered achlorhydric * patients taking drugs known as photosensitizers

Keywords: rosacea
effect of montelukast therapy in obstructive sleep apnea(osa) children

Conditions: Obstructive Sleep Apnea

Summary: the investigators leading hypotheses are: * oral therapy with montelukast may lead to improved sleep study findings in children with mild to moderate obstructive sleep apnea syndrome (osas) who require surgical removal of adenoids and tonsils for osas. * a significant proportion of the children with osas treated with montelukast will show reduced severity of osas, and this will remove the need for surgical intervention.


Eligibility criteria:
inclusion criteria: * eligible for inclusion in the study will be symptomatic snoring children \>2 years of age and \ 2/hrtst (hour total sleep time), and in whom t\&a is therefore contemplated. also among these, we will include children referred for evaluation for snoring who have a history of allergic rhinitis. exclusion criteria: * exclusion criteria will include: hypersensitivity to montelukast, immunodeficiency or immunosuppressant therapy, craniofacial, neuromuscular, syndromic or defined genetic abnormalities, acute upper respiratory tract infection, systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the study, and children who already had adenotonsillectomy. in addition, children chronically receiving oral antihistamine preparations or nasal decongestants will be required to continue using these medications throughout the duration of the study. patients receiving immunotherapy will continue on the same regimen without escalation of dose and frequency throughout the duration of the study. in addition, patients with severe osa who in the opinion of their treating physicians require early surgical intervention for their osa will be excluded from eligibility to the study.

Keywords: children sleep obstructive sleep apnea
study evaluating vabicaserin in subjects with schizophrenia

Conditions: Schizophrenia

Summary: the primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (sca-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.


Eligibility criteria:
inclusion criteria: * generally healthy, men and women, aged 18 to 65. * hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year. * ability to remain hospitalized for the duration of the screening period and for 4 weeks of double-blind treatment. exclusion criteria: * current axis i primary psychiatric diagnosis other than schizophrenia (dsm-iv-tr criteria). * current diagnosis or history of substance abuse or dependence (dsm-iv-tr criteria), including alcohol (except for nicotine), within 3 months before baseline (day -1). * subjects taking high or chronic doses of benzodiazepine at the screening evaluation who, in the investigator's judgment, would be likely to have severe withdrawal symptoms upon discontinuation.
stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer

Summary: this phase i trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

primary objectives: i. to determine the maximum tolerated dose (mtd) with an upper limit of 45 gray (gy) in 5 fractions, in the delivery of stereotactic body radiation therapy (sbrt) to the prostate fossa. secondary objectives: i. to assess acute and late toxicities from treatment. ii. to assess biochemical progression-free survival. iii. to collect prospective quality-of-life data related to bowel, urinary, and sexual health. outline: this is a dose-escalation study. patients receive 5 fractions of sbrt over 1.5 weeks. after completion of study treatment, patients are followed up at 90 days and then periodically for 3 years.

Eligibility criteria:
inclusion criteria: * history of diagnosis of prostate cancer after undergoing prostatectomy * no evidence of regional nodal or distant metastases based on computed tomography (ct) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on ct imaging will also be deemed non-neoplastic * eastern cooperative oncology group (ecog) performance scale 0-2 * child bearing potential: in this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable * prostate specific antigen (psa) value can be undetectable up to a value of 2.0 within 30 days prior to study entry * psa value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion * all subjects must have the ability to understand and the willingness to sign a written informed consent exclusion criteria: * patients should not have any uncontrolled illness including ongoing or active infection * patients may not be receiving any other investigational agents, or concurrent biological chemotherapy * patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years * study-specific exclusions: * history of prior radiation to the pelvis * history of uncontrolled inflammatory bowel disease * unable to comply with radiation therapy procedures * subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
sofosbuvir/velpatasvir fixed-dose combination in hcv-infected adults who are undergoing liver transplantation

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (sof/vel) fixed-dose combination (fdc) in hepatitis c virus (hcv)-infected adults who are undergoing liver transplantation.


Eligibility criteria:
key inclusion criteria: * hcv-infected, male and non-pregnant/non-lactating females, who are undergoing liver transplantation key exclusion criteria: * receiving an hcv-infected liver * hiv or hepatitis b virus (hbv) co-infected note: other protocol defined inclusion/exclusion criteria may apply.
quality of life after denture relining

Conditions: Quality of Life

Summary: purpose: the aim of the present study was to analyze the impact of mandibular denture relining with soft or hard denture liners in the oral health related quality of life (ohrqol) of edentulous patients. the null hypothesis was that there would be no difference in ohrqol findings after mandibular denture relining between patient groups treated with hard or soft denture liners.

complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (mucopren soft; group 1; n=22) or a hard acrylic resin based denture liner (kooliner; group 2; control n=22) with chairside procedures. the ohip edent (oral health impact profile) questionnaire was given to patients prior to reline procedures (baseline-t0) and 90 days (t90) post relining. three possible answers and scores were proposed for each question: never (0), sometimes (1) and almost always (2). results were analyzed by means of the generalized linear model (p≤0.05) considering two factors: time (t0 and t90) and group (hard and soft denture liners).

Eligibility criteria:
inclusion criteria: * edentulous in both jaws * complete denture wearers * clinically acceptable occlusal relationships * healthy mucosa, i.e. with no signs of inflammation, traumatic lesions, candidiasis or hyperplasia. exclusion criteria: * residual vertical bone height of 10 mm or less * no attached mucosa in any region of mandible (type e) * dentures with deteriorated intaglio surfaces * dentures with large pre-existing fractures * dentures with severely altered occlusal vertical dimension * extremely worn artificial teeth * dentures with unsatisfactory occlusions * neurological diseases * lack of motor coordination * difficulty of understanding instructions and the conditions of the study * patients with residual roots, cysts or bone spicules * patients with allergies to methyl methacrylate or silicone * knife-edge mandibular ridges.

Keywords: edentulism denture liner prosthodontics ohip edent
single-arm open-label multicenter study of vb-111 in patients with recurrent glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: the purpose of this study is to evaluate the safety, tolerability and efficacy of vb-111 in patients with relapsed glioblastoma multiforme.


Eligibility criteria:
inclusion criteria: 1. subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or gliosarcoma; 2. measurable disease by rano criteria; 3. disease progression or recurrence following standard of care treatment with temozolomide and radiation; 4. an interval of at least 4 weeks between prior surgical resection and study enrollment; 5. an interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from prior chemotherapy, and enrollment in this protocol; 6. recovered to grade 1 or less from the toxic effects of any earlier intervention; 7. karnofsky performance status \> 60% exclusion criteria: 1. prior anti-angiogenic therapy including vegf sequestering agents (ie bevacizumab, aflibercept, etc) or vegfr inhibitors (cediranib, pazopanib, sunitinib, sorafenib, etc); 2. prior stereotactic radiotherapy; 3. active infection; 4. evidence of cns haemorrhage ctcae grade 2 or above on baseline mri; 5. subjects who suffered from an acute cardiac event within the last 12 months; 6. subjects with active vascular disease, either myocardial or peripheral; 7. subjects with proliferative and/or vascular retinopathy; 8. subjects with known active second malignancy;

Keywords: relapsed glioblastoma multiforme, gbm
shoulder functional performance after shoulder surgery

Conditions: Rotator Cuff Tears

Summary: rotator cuff (rc) injuries are a progressive clinical condition that starts with an acute tendonitis, continues with partial thickness rupture and results in a full thickness rupture in the advanced period. arthroscopic rc repair is effective in the acute rc ruptures treatment caused by traumatic events. in the acute period after arthroscopic rc repair, shoulder joint range of motion (rom), muscle strength and shoulder functionality are decreased and daily activities are adversely affected. in the long-term, many studies have reported that these symptoms gradually decreaced. many studies investigating postoperative treatment of rc rupture have mostly focused on parameters such as postoperative pain, functionality, muscle strength, rom and quality of life.evaluation of these clinical parameters is necessary for patient follow-up in the early period. however, it is unclear whether the biomechanical etiologic factors continue that lead to rc rupture in the advanced period after surgery. therefore, the objective of this study was functional performance of shoulder after arthroscopic rotator cuff repair and ınvestigation of performance related factors.

design: observational cross-sectional study.

Eligibility criteria:
inclusion criteria: * with the same rc surgical procedure and technique, * with acromioplasty and/or tenodesis with rc repair, * undergoing arthroscopic rc repair from the upper extremity of the dominant side, * having completed the 12th week after surgery, * performing 90° and above active shoulder elevation movement exclusion criteria: * having undergone revision surgery or previous shoulder surgery, a history of fracture of the upper extremity * having undergone surgery causing limitation of motion in the spine, * having a neurological and/or vestibular and/or rheumatologic disease, * participants with diabetes mellitus, hypertension, cardiovascular and chronic respiratory disease that may cause problems during the test